^
Association details:
| Biomarker: | PCM1-JAK2 fusion |
|---|---|
| Cancer: | Chronic Eosinophilic Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia
Excerpt:
Continuing ruxolitinib as single agent, the eosinophil count remained normal. Marrow examinations after 11 and 15 months ruxolitinib therapy were hypocellular without evidence of CEL. After 15 months, a complete cytogenetic response (0 abnormal of 26 analyzed metaphases) was reached; and the number of interphase nuclei with a JAK2/9p24 breakpoint in FISH had equally decreased to less than 5%.
DOI:
https://doi.org/10.1182/blood-2012-06-433821
